KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (2016 - 2025)

Regeneron Pharmaceuticals has reported Shares Outstanding over the past 17 years, most recently at $137.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $137.6 million for Q4 2025, up 1.18% from a year ago — trailing twelve months through Dec 2025 was $137.6 million (up 1.18% YoY), and the annual figure for FY2025 was $137.6 million, up 1.18%.
  • Shares Outstanding for Q4 2025 was $1.8 million at Regeneron Pharmaceuticals, down from $136.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for REGN hit a ceiling of $136.2 million in Q3 2025 and a floor of $1.8 million in Q2 2021.
  • Median Shares Outstanding over the past 5 years was $61.8 million (2021), compared with a mean of $66.6 million.
  • Biggest five-year swings in Shares Outstanding: crashed 1050.0% in 2021 and later soared 7461.11% in 2025.
  • Regeneron Pharmaceuticals' Shares Outstanding stood at $1.8 million in 2021, then soared by 7144.44% to $130.4 million in 2022, then plummeted by 98.62% to $1.8 million in 2023, then surged by 7455.56% to $136.0 million in 2024, then increased by 1.18% to $137.6 million in 2025.
  • The last three reported values for Shares Outstanding were $137.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.